U.S. Markets closed
  • S&P 500

    4,432.99
    -40.76 (-0.91%)
     
  • Dow 30

    34,584.88
    -166.44 (-0.48%)
     
  • Nasdaq

    15,043.97
    -137.96 (-0.91%)
     
  • Russell 2000

    2,236.87
    +3.96 (+0.18%)
     
  • Crude Oil

    71.96
    -0.65 (-0.90%)
     
  • Gold

    1,753.90
    -2.80 (-0.16%)
     
  • Silver

    22.42
    -0.33 (-1.44%)
     
  • EUR/USD

    1.1732
    -0.0040 (-0.3402%)
     
  • 10-Yr Bond

    1.3700
    +0.0390 (+2.93%)
     
  • Vix

    20.81
    +2.12 (+11.34%)
     
  • GBP/USD

    1.3737
    -0.0059 (-0.4286%)
     
  • USD/JPY

    109.8950
    +0.1770 (+0.1613%)
     
  • BTC-USD

    48,717.72
    +790.79 (+1.65%)
     
  • CMC Crypto 200

    1,193.48
    -32.05 (-2.62%)
     
  • FTSE 100

    6,963.64
    -63.84 (-0.91%)
     
  • Nikkei 225

    30,500.05
    +176.71 (+0.58%)
     

Corcept Therapeutics Stock Drops After Disappointing Interim Data From Relacorilant Plus Nab-Paclitaxel Trial In Pancreatic Cancer

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Corcept Therapeutics Incorporated (NASDAQ: CORT) has announced preliminary results from its Phase 3 RELIANT trial of relacorilant for metastatic pancreatic cancer.

  • The trial evaluated relacorilant plus nab-paclitaxel in pancreatic cancer patients who had relapsed following at least two prior lines of therapy.

  • 2/31 evaluable patients exhibited tumor shrinkage designated as a partial response, a response rate of 6%, while 15 patients achieved stable disease for at least 12 weeks.

  • The combination was well-tolerated.

  • "Apparent level of benefit does not justify its further study as a treatment for end-stage pancreatic cancer, and we will not pursue an approval unless we believe our candidate therapy offers a substantial benefit," added Joseph K. Belanoff, MD, Corcept's Chief Executive Officer.

  • Enrollment for the trial is stopped.

  • The will initiate a Phase 2 trial of relacorilant plus nab-paclitaxel in patients with platinum-resistant ovarian cancer in Q1 of 2022.

  • Price Action: CORT shares are down 7.75% at $21.2 during the market session on the last check Tuesday.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.